FDA Actions

October 2009
Travel Medicine Advisor;Sep2009 Supplement, p2
The article presents updates related to the Food and Drug Administration (FDA). It states that the FDA requires new labelings on tumor necrosis factor (TNF)-blockers that include a revised Medication Guide that show the safety information as well as warnings about malignancies in adolescents and children who took the drugs. It adds that FDA has approved a new dipeptidyl peptidase-4 (dpp-4) inhibitor for type 2 diabetes. Moreover, FDA reviews reports of liver injury in patients taking orlistat.


Related Articles

  • Don't ask, don't tell. Conlan, Michael F. // Drug Topics;4/24/95, Vol. 139 Issue 8, p58 

    Reports on the effort of the Food and Drug Administration (FDA) to protect the identities of pharmacists and other health professionals who voluntarily submit reports of adverse drug and device events. FDA rule's preemption of any state or local law or regulation requiring disclosure;...

  • Two new diabetes drugs on the market.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p35 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of two drugs indicated for the treatment of type 2 diabetes.

  • FDA restricts Rezulin use.  // Drug Store News;7/19/99, Vol. 21 Issue 11, pCP10 

    Reports the restriction made by the United States Food and Drug Administration (FDA) on the use of Warner-Lambert Co.'s Rezulin and revoked the drug's approval for use as monotherapy of patients with type II diabetes. Condition imposed by the FDA on Warner-Lambert concerning the use of the...

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

  • Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. HIRSHBERG, BOAZ; RAZ, ITAMAR // Diabetes Care;May2011 Supplement 2, Vol. 34, pS101 

    The article examines the drivers for the regulations of the U.S. Food and Drug Administration related to cardiovascular (CV) safety of type 2 diabetes treatments as well as its impact on the development of novel anti-diabetes drugs. According to results of outcome studies, a surrogate biomarker...

  • FDA approved liraglutide to treat type 2 diabetes.  // Endocrine Today;Feb2010, Vol. 8 Issue 2, p2 

    The article reports that the U.S. Food and Drugs Administration (FDA) approved the use of liraglutide to treat type 2 diabetes.

  • Linagliptin now FDA-approved for type 2 diabetes.  // Endocrine Today;Jun2011, Vol. 9 Issue 6, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the use of Linagliptin to improve blood glucose control in adult patients with type 2 diabetes.

  • Amaryl approved for diabetes.  // Drug Topics;12/11/95, Vol. 139 Issue 23, p8 

    Reports on the Food and Drug Administration's approval of Hoechst Marion Roussel's Amaryl, an oral sulfonylurea, for the treatment of non-insulin-dependent diabetes mellitus.

  • FDA actions.  // Neurology Alert;Jul2011 Pharmacology Watch, p2 

    The article reports on the actions taken by the U.S. Food and Drug Administration on several drugs including the approval of linagliptin for type 2 diabetes in adults and rilpivirine for adults with HIV-1 and the eventual pulling out of Rosiglitazone (Avandia) from the U.S. market.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics